These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 2446320

  • 1. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).
    Sundquist WI, Lippard SJ, Stollar BD.
    Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320
    [Abstract] [Full Text] [Related]

  • 2. Binding of cis- and trans-diamminedichloroplatinum(II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies.
    Sundquist WI, Lippard SJ, Stollar BD.
    Biochemistry; 1986 Apr 08; 25(7):1520-4. PubMed ID: 3707890
    [Abstract] [Full Text] [Related]

  • 3. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
    Terheggen PM, Floot BG, Lempers EL, van Tellingen O, Begg AC, den Engelse L.
    Cancer Chemother Pharmacol; 1991 Apr 08; 28(3):185-91. PubMed ID: 1855275
    [Abstract] [Full Text] [Related]

  • 4. Polyclonal antibodies elicited against trans-diamminedichloroplatinum(II)-modified DNA and their application in nonradioactive hybridization experiments.
    Brabec V, Vrana O, Kiseleva VI, Poverenny AM.
    Eur J Biochem; 1991 Nov 01; 201(3):723-30. PubMed ID: 1935966
    [Abstract] [Full Text] [Related]

  • 5. Antibodies against (1R,2R)-cyclohexanediamineplatinum(II)-DNA adduct recognize the conformational differences of isomeric analogues of cyclohexanediamine.
    Yamada H, Kato T, Hirose J, Inagaki K, Noji M, Kidani Y.
    Biochim Biophys Acta; 1990 Jul 30; 1049(3):298-302. PubMed ID: 2383586
    [Abstract] [Full Text] [Related]

  • 6. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.
    Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D, Yuspa SH.
    Proc Natl Acad Sci U S A; 1982 Nov 30; 79(21):6443-7. PubMed ID: 6959129
    [Abstract] [Full Text] [Related]

  • 7. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
    Donahue BA, Augot M, Bellon SF, Treiber DK, Toney JH, Lippard SJ, Essigmann JM.
    Biochemistry; 1990 Jun 19; 29(24):5872-80. PubMed ID: 2383564
    [Abstract] [Full Text] [Related]

  • 8. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication.
    Heiger-Bernays WJ, Essigmann JM, Lippard SJ.
    Biochemistry; 1990 Sep 11; 29(36):8461-6. PubMed ID: 2174701
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
    Lippert B.
    Met Ions Biol Syst; 1996 Sep 11; 33():105-41. PubMed ID: 8742842
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
    Reed E, Gupta-Burt S, Litterst CL, Poirier MC.
    Carcinogenesis; 1990 Dec 11; 11(12):2117-21. PubMed ID: 1979937
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
    Dedon PC, Borch RF.
    Biochem Pharmacol; 1987 Jun 15; 36(12):1955-64. PubMed ID: 2954556
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents.
    Hollis LS, Sundquist WI, Burstyn JN, Heiger-Bernays WJ, Bellon SF, Ahmed KJ, Amundsen AR, Stern EW, Lippard SJ.
    Cancer Res; 1991 Apr 01; 51(7):1866-75. PubMed ID: 2004370
    [Abstract] [Full Text] [Related]

  • 16. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
    Comess KM, Burstyn JN, Essigmann JM, Lippard SJ.
    Biochemistry; 1992 Apr 28; 31(16):3975-90. PubMed ID: 1314653
    [Abstract] [Full Text] [Related]

  • 17. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
    Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J.
    Biochemistry; 1985 Jan 29; 24(3):707-13. PubMed ID: 4039603
    [Abstract] [Full Text] [Related]

  • 18. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA.
    Payet D, Gaucheron F, Sip M, Leng M.
    Nucleic Acids Res; 1993 Dec 25; 21(25):5846-51. PubMed ID: 8290343
    [Abstract] [Full Text] [Related]

  • 19. S1 nuclease sensitivity to cis- and trans-diamminedichloroplatinum(II) modified DNAS: influence of (G+C) content and nucleotide sequence.
    Scovell WM, Capponi VJ.
    Biochem Biophys Res Commun; 1984 Oct 30; 124(2):367-74. PubMed ID: 6093796
    [Abstract] [Full Text] [Related]

  • 20. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
    Roberts JJ, Friedlos F.
    Cancer Res; 1987 Jan 01; 47(1):31-6. PubMed ID: 3791217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.